Scarica l'app Stockscreener
40.92
0.73%
0.27
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Royalty Pharma Plc Borsa (RPRX) Ultime notizie
Royalty Pharma (NASDAQ:RPRX) Sets New 1-Year HighHere's Why - MarketBeat
United StatesGoodwin Guides Royalty Pharma On Acquisition Of Remaining Royalty Interest In Roche’s Evrysdi For $240 Million And Potential Milestones - Mondaq
Financiere des Professionnels Fonds d investissement inc. Invests $933,000 in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma Acquires Remaining Royalty Interest in Roche’s Evrysdi for $240 Million and Potential Milestones - citybiz
Why (RPRX) Price Action Is Critical for Tactical Trading - Stock Traders Daily
What's Going On With Royalty Pharma Stock Wednesday?Royalty Pharma (NASDAQ:RPRX) - Benzinga
Royalty Pharma buys remaining royalty interest in Roche drug Evrysdi - MSN
Royalty Pharma Acquires Remaining Evrysdi Royalties From PTC Therapeutics - Nasdaq
Royalty Pharma acquires final portion of Evrysdi royalty for $240 million By Investing.com - Investing.com Nigeria
PTC Therapeutics IncCo, Royalty Pharma Inv - 富途牛牛
Royalty Pharma acquires remaining royalty interest in Roche's Evrysdi for $240 million - marketscreener.com
Royalty Pharma Buys Remaining Royalty Interest in Roche's Evrysdi - marketscreener.com
Royalty Pharma acquires final portion of Evrysdi royalty for $240 million - Investing.com
Royalty Pharma (NASDAQ:RPRX) EVP Sells $786,400.00 in Stock - MarketBeat
Royalty Pharma stock rises after acquiring full Evrysdi royalty By Investing.com - Investing.com Canada
Royalty Pharma stock rises after acquiring full Evrysdi royalty - Investing.com
Royalty Pharma Acquires Final Portion of Evrysdi Royalty from PTC Therapeutics for $240 Million - Quiver Quantitative
Royalty Pharma acquires remaining Evrysdi royalty for $240 million - StreetInsider
Nuvalent’s royalty interest acquired by Royalty Pharma - MSN
Royalty Pharma PLC $RPRX Shares Sold by Marathon Asset Management Ltd - MarketBeat
Royalty Pharma announces planned legal leadership transition - MSN
Royalty Pharma Plc's (NASDAQ:RPRX) Earnings Haven't Escaped The Attention Of Investors - 富途牛牛
World Investment Advisors Takes $1.70 Million Position in Royalty Pharma PLC $RPRX - MarketBeat
Can Royalty Pharma plc (RPD) stock ride next bull market cycleReal Estate Investment Trusts & Capitalize On Fast Trends - bollywoodhelpline.com
Royalty Pharma PLC $RPRX Stock Holdings Lifted by Voya Investment Management LLC - MarketBeat
Swedbank AB Acquires 42,800 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Friedenthal Financial Acquires Shares of 29,322 Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma (RPRX): Reassessing Valuation After MYQORZO’s FDA Approval Unlocks New Royalty Cash Flows - Sahm
Royalty Pharma (NASDAQ:RPRX) EVP Sells $767,600.00 in Stock - MarketBeat
Royalty Pharma Announces Planned Legal Leadership Transition - TipRanks
Royalty Pharma names McGivern as chief legal officer - StreetInsider
Royalty Pharma plc Announces Executive Changes - marketscreener.com
The Technical Signals Behind (RPRX) That Institutions Follow - Stock Traders Daily
Royalty Pharma Gains from MYQORZO FDA Approval - TradingView — Track All Markets
Royalty Pharma (NASDAQ:RPRX) EVP Sells $3,060,375.22 in Stock - MarketBeat
Insider Selling: Royalty Pharma (NASDAQ:RPRX) EVP Sells 30,654 Shares of Stock - MarketBeat
Royalty Pharma : Q4 2025 Pre-Quarterly Results Communication - marketscreener.com
How risky is Royalty Pharma plc (RPD) stock compared to peersPortfolio Update Summary & AI Powered Buy and Sell Recommendations - ulpravda.ru
Royalty Pharma PLC $RPRX Shares Sold by Thrivent Financial for Lutherans - MarketBeat
Dividend Watch: How Royalty Pharma plc stock compares to growth peers - Улправда
Insider Selling: Royalty Pharma (NASDAQ:RPRX) CFO Sells 69,582 Shares of Stock - MarketBeat
Royalty Pharma (NASDAQ:RPRX) EVP Marshall Urist Sells 20,000 Shares - MarketBeat
Royalty Pharma Insider Sold Shares Worth $766,420, According to a Recent SEC Filing - marketscreener.com
VP Urist Sells 20,000 ($766.4K) Of Royalty Pharma PLC [RPRX] - TradingView — Track All Markets
[Form 4] Royalty Pharma plc Insider Trading Activity - Stock Titan
UBS reiterates Buy rating on Nuvalent stock, citing Royalty Pharma deal - Investing.com Nigeria
Royalty Pharma buys royalty interest in Nuvalent cancer drugs for up to $315 mln - MSN
Royalty Pharma PLC (NASDAQ:RPRX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Shareholder Sandy Lamm LLC Files To Sell 160,000 Of Royalty Pharma PLC [RPRX] - TradingView — Track All Markets
2.11%
0.16%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):